A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

Inclusion Criteria:

• Participant's parent(s)/guardian(s) must be willing to provide written informedconsent and the participant must provide informed assent before any study-specificprocedures are performed;

• Participant must be aged 6-17 years old and willing to swallow tablets;

• Participant must weigh at least 16 kilograms (kg);

• Participant must have a diagnosis of HeFH prior to receiving the first dose of studymedication at Treatment Visit T1 per Make Early Diagnosis to Prevent Early Deathsproject (MEDPED) criteria by meeting at least one of the following clinicalcriteria:

1. Documented diagnosis of HeFH determined by positive genetic testing; or

2. Documented LDL-C or TC meeting one or more of the following criteria: i. LDL-C >200 milligrams per deciliter (mg/dL) (5.2 millimole per liter [mmol/L]) orTC >270 mg/dL (7.0 mmol/L), with no first- second- or third-degree relative withdocumented FH diagnosis (general population); or ii. LDL-C >155 mg/dL (4.0 mmol/L)or TC >220 mg/dL (5.7 mmol/L), and also having a first-degree relative withdocumented familial hypercholesterolemia (FH) diagnosis; or iii. LDL-C >165 mg/dL (4.3 mmol/L) or TC >230 mg/dL (5.9 mmol/L), and also having a second-degree relativewith documented FH diagnosis; or iv. LDL-C >170 mg/dL (4.4 mmol/L) or TC >240 mg/dL (6.2 mmol/L), and also having a third-degree relative with documented FH diagnosis

• Current treatment with approved stable lipid-modifying therapy (LMT), including anoptimal dose of statin with or without other LMT(s), at stable dose for at least 4weeks prior to Treatment Visit T1 (6 weeks for fibrates; however, gemfibrozil is notallowed in participants taking a statin as per coadministration instructions definedin the statin label). Participants must remain on that stable dose throughout theduration of the trial. Optimal dose of statin will be determined by the investigatorusing their medical judgment and available sources, including the participant'sself-reported history of LMT. A participant's optimal dose of statin is defined asmeeting one of the following criteria:

1. the highest approved dose of statin prescribed for the age of the participantbased on regional practice or local guidelines; or

2. less than the highest approved dose of statin, including no statin, prescribedfor the age of the participant based on regional practice or local guidelines (including no statin) if: i. the participant has previously taken 2 or morestatin therapies at any dose and not able to tolerate or unresponsive due totheir mutations (null); or ii. the participant has previously taken 1 or morestatin therapies at any dose and is unwilling to attempt another statin at anydose or advised by a physician to not attempt another statin at any dose.

3. Participant/parent and investigator attestation to the participant'sunwillingness to attempt and/or physician advice to not attempt additionalstatin therapy will be recorded.

Exclusion Criteria:

• Participant has a diagnosis of homozygous familial hypercholesterolemia (HoFH) orcompound HeFH;

• Participant has a fasting triglyceride (TG) level ≥400 mg/dL (4.5 mmol/L);

• Participant has uncontrolled hypothyroidism, including a value forthyroid-stimulating hormone (TSH) < lower limit of normal (LLN) or >1.5 × the upperlimit of normal (ULN);

• Participant has liver disease or dysfunction, including:

1. positive serology for hepatitis B surface antigen (HBsAg) and/or hepatitis Cvirus antibodies (HCV-AB), or

2. serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value ≥2 × ULN and/or serum total bilirubin (TB) value ≥2 × ULN. If the serum TBvalue is ≥1.2 × ULN, a reflex indirect (unconjugated) bilirubin will beobtained and, if consistent with Gilbert's disease or if the participant has ahistory of Gilbert's disease, the participant may be enrolled in the study.

• Participant has renal dysfunction or glomerulonephritis, including an estimatedglomerular filtration rate (eGFR) <75 milliliters/minute/1.73 square meter (mL/min/1.73 m^2).

Other protocol defined inclusion and exclusion criteria.